Growth Analyser Growth Analyser

Compare funds

Pick up to 10 funds. Compare funds from the same category for a fair reading.

Invesco India Pharma and Healthcare Fund · Direct ✕Bajaj Finserv Healthcare Fund · Direct ✕

Growth of ₹10,000

Basics

Invesco India Pharma and Healthcare FundBajaj Finserv Healthcare Fund
CategorySectoral / ThematicSectoral / Thematic
PlanDirectDirect
Fund houseInvescoBajaj Finserv
NAV₹10.7800₹12.5590
NAV date20 Nov 202620 Nov 2026
History2 months1.9 years
Expense ratio1.9%0.9%
StarsNot ratedNot rated
Growth Score——

Returns

Invesco India Pharma and Healthcare FundBajaj Finserv Healthcare Fund
1 month+19.78%+11.63%
3 months—+3.77%
6 months—+17.14%
YTD—+28.13%
1 year—+25.26%
3 years (CAGR)——
5 years (CAGR)——
10 years (CAGR)——
Since launch+7.58%+12.33%

Risk

Invesco India Pharma and Healthcare FundBajaj Finserv Healthcare Fund
Volatility——
Downside volatility——
Sharpe——
Sortino——
Calmar——
Return / risk——
Deepest fall−11.39%−15.68%
Days to recover14262
Below its high+0.00%−0.19%

Against benchmark

Invesco India Pharma and Healthcare FundBajaj Finserv Healthcare Fund
Alpha——
Beta——
R²——
Up capture——
Down capture——
Tracking error——
Information ratio——
Treynor——

Consistency

Invesco India Pharma and Healthcare FundBajaj Finserv Healthcare Fund
Best 1-year—+27.12%
Middle 1-year—+13.16%
Worst 1-year—−4.21%
1-year periods with a loss—10.4%
Middle 3-year——
Positive months——
Best day+3.62%+2.94%
Worst day−2.74%−2.66%
Worst 5% day−1.53%−1.48%
Positive days48.9%54.4%
NAVs a year48247

SIP of ₹10,000 a month

Invesco India Pharma and Healthcare FundBajaj Finserv Healthcare Fund
5-year XIRR——
5-year value——
3-year XIRR——
1-year XIRR—+36.68%

Holdings overlap i

Overlap compares the shares two funds hold, so it needs at least two of these funds with shares in a loaded monthly filing.
  • Invesco India Pharma and Healthcare Fund: no monthly portfolio filing from Invesco is loaded yet, so it is left out here.
  • Bajaj Finserv Healthcare Fund: no monthly portfolio filing from Bajaj Finserv is loaded yet, so it is left out here.

Search Growth